2,192 results on '"Vey, Norbert"'
Search Results
2. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome
3. Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML
4. Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia
5. Disseminated Scedosporium Invasive Fungal Infection in Critically ill Newly Diagnosed Acute Myeloid Leukemia Patient Complicated with Cerebritis
6. GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation
7. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases
8. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
9. Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia
10. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG)
11. Downregulation of stromal syntenin sustains AML development
12. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
13. Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation
14. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML
15. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
16. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
17. RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia
18. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome
19. Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.
20. Treatment of Newly Diagnosed AML in Unfit Patients
21. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
22. Diagnosis and treatment of therapy-related acute myeloid leukemia
23. Epigenenomic and transcriptomic characterization of NPM1-mutated CN-AML subtypes
24. Herpesviridae in critically ill hematology patients: HHV-6 is associated with worse clinical outcome
25. The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute’s Experience
26. Inflammatory myopathies associated with myelodysplastic syndromes: A French multicenter case control study and literature review
27. BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells
28. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study
29. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
30. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia
31. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
32. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
33. Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines
34. Venetoclax Resistance in Acute Myeloid Leukemia
35. Tripartite prehabilitation of patients with acute myeloid leukaemia and high-risk myelodysplastic syndromes during intensive chemotherapy before allogeneic haematopoietic stem cell transplantation (COHABILIT): protocol for an innovating prospective multicentre study
36. A Single Center Real World Experience of Allogeneic HSCT of Patients with MDS/CMML in Aged Population
37. Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins
38. Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation
39. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
40. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
41. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients
42. Treatment of Newly Diagnosed AML in Unfit Patients
43. Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review
44. Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.
45. Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival
46. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
47. Comparison of HLA antibody identification methods for the selection of platelet products for HLA‐mediated platelet refractory patients
48. Feasibility of Cyclosporine Prophylaxis Withdrawal in Critically Ill Allogenic Hematopoietic Stem Cell Transplant Patients Admitted to the Intensive Care Unit With No GVHD
49. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions
50. Association between health literacy, communication and psychological distress among myelodysplastic syndromes patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.